ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the completion of Cannabis Wheaton Income Corp.’s (TSX.V: CBW) previously detailed purchase of $15 million of ABcann common shares at an agreed upon valuation of $2.25 per share.
All eyes are on ABcann Medicinals, Inc. as it prepares to go public. The company, which is already growing rapidly, wants to expand its footprint in Canada and take advantage of potential international opportunities.
On Thursday, ABcann Global Corporation (TSXV: ABCN) announced that it has retained the services of Dr. Michael Shannon as its chief medical consultant.
Recently acquired by ABcann Global Corporation, an acquisition that came with a $26.8 million capital raise to help expand production, the company is already licensed to sell to the entire Canadian market and plans to significantly expand production to reach this goal.
Going public appears to be paying off for ABcann Medicals (TSXV: ABCN), since the medical cannabis grower launched its initial public offering (IPO) on the TSX Venture Exchange.
Cannabis Wheaton Income Corp. (TSX VENTURE:CBW) is pleased to announce the appointment of Manon Grand-Maitre to the Advisory Board of Cannabis Wheaton.
Isodiol International Inc. (CSE:ISOL) (OTC:LAGBF) (Frankfurt:LB6A.F) a global cannabis innovator specializing in the development of pharmaceutical and consumer products announces unaudited July 2017 revenue numbers of its wholly owned subsidiary ISO International LLC of $1,358,787 USD .
Earlier this week, Sen. Cory Booker (D-NJ) introduced legislation that would begin to end the unfair prohibition of marijuana throughout the federal government. The bill would also serve to repair the damage done to the country via prohibition.
Booker was quoted stating that “I believe the federal government should get out of the illegal marijuana business. You see what’s happening around this country right now. Eight states and the District of Columbia have moved to legalize marijuana.
ChineseInvestors.com, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China.
One of the very first licensed producers and a pioneer in Canadian medical cannabis, ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) has always held to meticulous specifications in the production of its pharmaceutical grade, plant-based medicines.
The fastest-growing industry with the most consistent growth rate in North America is legal marijuana. A recent Forbes article says that the market could grow 700% by 2020.
Growing marijuana in North America, for obvious reasons, has historically been an underground affair. Amid growing legalization in favor of recreational and medicinal use, growing cannabis on mass scale is rapidly becoming a necessity for companies in a burgeoning industry driven by incredible consumer demand.
The backbone of medical advancement is biotechnology, an industry wrought with the incredible potential of novel drug R&D, but vulnerable to the risk of stringent regulatory approval processes. Within this volatile market, however, is the cannabis-biotech sub-sector – a market flourishing with opportunity, innovation, and deep roots of medical possibilities.
India Globalization Capital, Inc. (NYSE MKT: IGC) has set a long-term goal for itself in the U.S. of becoming a leading provider of cannabis-based pharmaceutical and nutraceutical products.
Investors have had their eyes on Algae Dynamics Corp. (OTCQB: ADYNF), which has partnered with various Canadian universities (including the University of Waterloo and Western University) for access to research and to boost its cannabis extraction expertise.
